**Abstract**

**Introduction:** Data on clinical outcomes with long-acting antipsychotic treatment in young, newly diagnosed patients with schizophrenia is sparse.

**OBJECTIVES:** To explore hospitalization, drug utilization and clinical outcomes from medical records of newly diagnosed schizophrenia patients during first 12 months of treatment with once-monthly paliperidone palmitate (PP).

**Methods:** International, multicenter, retrospective, observational study. Outcomes presented: baseline (BL) characteristics and demographics, clinically relevant improvements in disease severity (ie ≥20% decrease in PANSS or BPRS total score or CGI-S Change≥-2 or CGI-C≥3, with no score showing worsening) and clinically relevant functional improvement (ie change in PSP total score≥+7 points or change in GAF total score≥+20 points, with no score showing worsening) from BL to last-observation-carried-forward endpoint (LOCF-EP) within 12-month documentation period, mean mode PP dose and adverse drug reactions.

**Results**: 84 patients analyzed: 69% male, mean age at initiation of PP was 24.1(SD2.7) years, Mean BL weight was 78.7(SD16.0)kg and 80.0(SD14.7)kg at LOCF-EP, with a mean change of 1.2(SD3.9)kg; mean time from first psychotic episode to initiation of PP was 5.5(SD3.3) months. At LOCF-EP 86.6% achieved a clinically relevant improvement (71/84, Kaplan-Meier median time from initiation of PP: 52.4 days). 63.4% achieved a clinically relevant functional improvement (52/84, Kaplan-Meier median time from initiation of PP: 53.1 days). PP mean mode maintenance dose was 96.4(SD19.8) mg. ADRs reported in ≥5% of patients were weight increase 9.1% and hyperprolactinemia 5.7%.

**Conclusions:** Treatment with once-monthly PP was well tolerated and associated with clinically relevant improvements in disease severity and functioning in young, newly diagnosed schizophrenia patients.
